A Phase I/II Double-blind Safety and Efficacy Evaluation of Nowarta110 in Patients With Plantar Warts

Completed · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Plantar Warts

In brief

To evaluate drug safety and efficacy in patients treated with Nowarta110 and to determine therapeutic activity against Plantar Warts * Clinical Tolerance * Clinical Recovery * Evaluate Safety

Key facts

Study ID

NCT02338336

Run by

Nowarta Biopharma Inc

People needed

54

Starts

2015-02-01

Expected to finish

2015-12-01

Last updated by the study team

2016-11-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with refractory or recurrent Plantar Warts.
• No wart treatment for the last 12 weeks
• Healthy male or non-pregnant, non-lactating female aged ≥ 18 years or greater
• If female of childbearing potential, use an acceptable form of birth control during the study
• Provide written informed consent or (HIPAA consent/authorization, as applicable

You may not qualify if…

• Concurrent medical disorder or disease making implementation or interpretation of the protocol or results difficult or unsafe
• Female subjects who are breast-feeding or planning to become pregnant
• Patients with a history of allergy to silver or fruits
• Subjects with clinically significant unstable medical disorder, life threatening disease, or current malignancies
• Subjects with History of Alcohol abuse or other drug abuse within 2 years prior to Randomization
• Subjects who have been treated with an investigational drug or investigational device within a period of 30 days prior to study enrollment
• Concomitant Medications: any other wart therapy is prohibited during the study.

Where it is running

• Nowarta Biopharma Inc — Huntington Beach, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.